Polycythemia clinical trials

Explore recruiting polycythemia clinical trials.

Recruiting polycythemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Polycythemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera

Bulgaria, Poland, Germany, Italy, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Spain, Portugal, Belgium, Netherlands, Germany, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Atorvastatinbehandling til patienter med de Philadelphia-negative kronisk myeloproliferative neoplasier - essentiel trombocytose, polycythemia vera og præfibrotisk myelofibrose.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Polycythemia trials by city

Polycythemia in Toronto Polycythemia in Vancouver Polycythemia in Montreal Polycythemia in Calgary Polycythemia in Edmonton Polycythemia in Ottawa Polycythemia in Winnipeg Polycythemia in Quebec City Polycythemia in Hamilton Polycythemia in Kitchener Polycythemia in London Polycythemia in Halifax Polycythemia in New York Polycythemia in Los Angeles Polycythemia in Chicago Polycythemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease